Study drug for relapsed or hard-to-treat B-cell leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early study tests MK-1045 in people with precursor B-cell acute lymphoblastic leukemia (B-ALL) that has come back or did not respond to earlier treatment. It may help shrink leukemia and improve remission in patients with limited options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older, or you are between 2 and 17 years old
- You have precursor B-cell acute lymphoblastic leukemia (B-ALL), and at least 5% leukemia cells are found in bone marrow
- Your leukemia is “refractory” (did not respond) or has relapsed (come back) based on specific past-treatment timelines
- If your B-ALL is Ph-positive, you have had at least 2 prior targeted tablet medicines, or you have a specific mutation called T315I
- You have not had anti-CD19 treatment in the last 3 months and have not had CAR-T in the last 3 months
- You have no major problems that would raise safety risk, such as serious brain/spinal cord leukemia involvement, certain infections, major heart/stroke disease, or uncontrolled autoimmune disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
This trial tests a new drug called MK-1045 in patients whose acute lymphoblastic leukemia (a blood cancer) has come back or stopped responding to previous treatments. The goal is to see if this drug can help control the cancer when other options haven't worked.
This study tests a new drug called MK-1045 for people with follicular lymphoma or diffuse large B-cell lymphoma (two types of blood cancer) that hasn't responded to at least two previous treatments. The drug is designed to target cancer cells and may help people whose cancer has come back or stopped responding to therapy.
This trial tests an experimental drug called MK-1045 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to treatment. The drug targets a protein called CD19 on cancer cells, which may help the immune system fight the cancer.
This study tests a new injectable drug called BLB101 compared to a standard treatment (Blincyto) for adults with a type of leukemia called B-ALL that has come back or not responded to treatment. It may help you if your leukemia has the CD19 protein and you have had 1 to 2 previous treatments.
This trial tests a new drug called STR-P004 for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), a type of blood cancer. The goal is to see if the drug is safe and can help shrink or control the cancer.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.